Willett, Christopher G <br/><br/>
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Nov 2005 
 - 8136-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Letter 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2005.02.5635  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Biomarkers<br/>Combined Modality Therapy<br/>Dose-Response Relationship, Drug<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neovascularization, Pathologic--prevention & control<br/>Prognosis<br/>Radiotherapy Dosage<br/>Rectal Neoplasms--blood supply<br/>Survival Rate